Gene · 3752
KCND3: potassium voltage-gated channel subfamily D member 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCND3: potassium voltage-gated channel subfamily D member 3. Genes, record 3752. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3752
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UK17 | A-type voltage-gated potassium channel KCND3 | 655 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58784 | Q9UK17 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5257 | Q9UK17 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 4845 | Q9UK17 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2201 | Q9UK17 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2201 | Q9UK17 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 4845 | Q9UK17 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5257 | Q9UK17 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 30265 | Q9UK17 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 30265 | Q9UK17 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 30265 | Q9UK17 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| VERNAKALANT | CHEMBL2111112 | Voltage-gated potassium channel subunit Kv4.3 blocker | BLOCKER | ChEMBL |
| VERNAKALANT HYDROCHLORIDE | CHEMBL2107383 | Voltage-gated potassium channel subunit Kv4.3 blocker | BLOCKER | ChEMBL |
Trials96
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsNIH grants1,363
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCND3 papers | Newest fiscal year |
|---|---|---|---|
| R01HL092577 | IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL | 6 | 2025 |
| R01HL131517 | Sex-specific arrhythmogenic mechanisms of atrial fibrillation | 4 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 3 | 2025 |
| R01HL113006 | Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling | 3 | 2025 |
| R01HL141214 | Functional Microdomains in the Heart's Pacemaker: A New Dimension of Cardiac Remodeling | 3 | 2025 |
| P50AA022537 | Cross-species investigation of gene networks for ethanol-related behaviors | 2 | 2025 |
| R01AA011147 | Ethanol and aldehyde dehydrogenases in health and disease | 2 | 2025 |
| R01AI040127 | Signal transduction and gene induction in lymphocytes | 2 | 2025 |
| R01HL085844 | Functional interactions of cardiac ion channels | 2 | 2025 |
| R01HL128368 | Engineered Stem Cells for Cardiac Repair | 2 | 2025 |
1 to 10 of 1,363Source NIH's project files
See all 1,363 nih grantsPapers2,071
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis. | Neurotox Res | 2026 | 42821203 | PubTator, text mining | PubMed |
| Selective inhibition of LY294002 across cloned human cardiac ion channels: implications for atrium-selective therapy in atrial fibrillation. | Front Pharmacol | 2026 | 42780784 | PubTator, text mining | PubMed |
| Selectivity Filter KCND3 Variant Causes Spinocerebellar Ataxia 19/22 and KV4.3 Functional Loss. | Mov Disord | 2026 | 42712185 | PubTator, text mining | PubMed |
| Annexin A4 Deficient Ventricular Myocytes Display Advanced Hypertrophy and Electrical Remodeling With Chronic β-Adrenoceptor Stimulation. | FASEB J | 2026 | 42684683 | PubTator, text mining | PubMed |
| Characterization of an early-diverging KCNE potassium-channel auxiliary subunit in the jawless vertebrate lamprey. | Elife | 2026 | 42647063 | PubTator, text mining | PubMed |
| Ceramide-Mediated Lipotoxicity: A Metabolic Driver of Myocardial Dysfunction in Heart Failure with Preserved Ejection Fraction. | Curr Cardiol Rev | 2026 | 42509675 | PubTator, text mining | PubMed |
| The interplay between dynamic regulation of ion-channel gating and trafficking in cardiac arrhythmogenesis. | J Physiol | 2026 | 42330017 | PubTator, text mining | PubMed |
| ARumenamides as Multitarget Ion Channel Modulators: Insights from Fenestration-Focused Docking, ADMET Profiling, and Molecular Dynamics. | Int J Mol Sci | 2026 | 42278315 | PubTator, text mining | PubMed |
| Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806. | Pharmacol Res Perspect | 2026 | 42135999 | PubTator, text mining | PubMed |
| Integrative Single- and Multi-Trait GWASs Identify Pleiotropic Loci Affecting Growth and Egg Production in Zhedong Geese. | Animals (Basel) | 2026 | 41976052 | PubTator, text mining | PubMed |
1 to 10 of 2,071
See all 2,071 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3752
GET https://conductscience.org/api/genes/v1/3752/patents?page=2